![Robert Zeldin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Zeldin
Hoofd Techniek/Wetenschap/O&O bij
MEIRAGTX HOLDINGS PLC
Vermogen: 2 M $ op 31-07-2026
Profiel
Robert K.
Zeldin is currently Chief Medical Officer at MeiraGTx Holdings Plc since 2020.
Former positions include Chief Medical Officer & Executive Vice President at Acceleron Pharma, Inc. from 2018 to 2019; Chief Medical Officer at Immunovant, Inc. from 2019 to 2020; Chief Medical Officer at Ablynx NV from 2015 to 2018; Senior Vice President-Global Clinical Development at Stallergenes SAS from 2011 to 2015; Vice President at Novartis Pharmaceuticals Corp.
from 2005 to 2010; and Medical Officer roles at the US Food & Drug Administration and the Center for Biologics Evaluation & Research.
Education includes undergraduate studies at The Johns Hopkins University and a doctorate from Tufts University School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 25-06-2026 | 171.801 ( 0,19% ) | 2 M $ | 31-07-2026 |
Actieve functies van Robert Zeldin
| Bedrijven | Functie | Begin |
|---|---|---|
| MEIRAGTX HOLDINGS PLC | Hoofd Techniek/Wetenschap/O&O | 05-08-2020 |
Eerdere bekende functies van Robert Zeldin
| Bedrijven | Functie | Einde |
|---|---|---|
| IMMUNOVANT, INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2020 |
| ACCELERON PHARMA INC. | Hoofd Techniek/Wetenschap/O&O | 05-04-2019 |
| ABLYNX | Hoofd Techniek/Wetenschap/O&O | 01-01-2018 |
| STALLERGENES | Hoofd Techniek/Wetenschap/O&O | 01-01-2015 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Corporate Officer/Principal | 01-01-2010 |
Opleiding van Robert Zeldin
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
67
Eerstegraads connecties
10
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 10 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company which develops protein therapeutics for cancer and orphan diseases | Health Technology |
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products used for the treatment of allergy-related respiratory diseases | Health Technology |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Develops and produces antibodies | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Health Technology |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Government |
Center for Biologics Evaluation & Research
 Center for Biologics Evaluation & Research Miscellaneous Commercial ServicesCommercial Services Engages in conducting research to promote safe and appropriate use of biological products | Commercial Services |
Tufts University School of Medicine
 Tufts University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MeiraGTx Holdings Plc
 MeiraGTx Holdings Plc BiotechnologyHealth Technology Develops and manufactures genetic medicines | Health Technology |
Immunovant, Inc.
 Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
